These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 2509529

  • 21. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) InvestigatorsThe CAPS Coordinating Center, University of Washington, JD-22, 1107 Northeast 45th, Room 505, Seattle, Washington 98105, USA..
    Am J Cardiol; 1988 Mar 01; 61(8):501-9. PubMed ID: 2894169
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the efficacy of newly developed antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias.
    Hellestrand KJ.
    Eur Heart J; 1984 Sep 01; 5 Suppl B():87-94. PubMed ID: 6437822
    [No Abstract] [Full Text] [Related]

  • 23. Selection of an antiarrhythmic drug for a sudden-death-prevention trial.
    Woosley RL, Roden DM, Duff HJ, Oates JA.
    Am Heart J; 1982 Apr 01; 103(4 Pt 2):737-45. PubMed ID: 6175198
    [Abstract] [Full Text] [Related]

  • 24. [Electrophysiological classification of newer antiarrhythmic drugs (author's transl)].
    Schmitz W.
    Klin Wochenschr; 1980 Sep 15; 58(18):907-18. PubMed ID: 6110804
    [Abstract] [Full Text] [Related]

  • 25. The use of tocainide, encainide, lorcainide and flecainide for supraventricular arrhythmias.
    Orning OM.
    Eur Heart J; 1984 Sep 15; 5 Suppl B():81-6. PubMed ID: 6437821
    [No Abstract] [Full Text] [Related]

  • 26. Class IB antiarrhythmic drugs: tocainide, mexiletine, and moricizine.
    Snyder DW.
    J La State Med Soc; 1989 May 15; 141(5):21-5. PubMed ID: 2499645
    [Abstract] [Full Text] [Related]

  • 27. Aggravation of ventricular arrhythmia. A drug-induced complication.
    Podrid PJ.
    Drugs; 1985 May 15; 29 Suppl 4():33-44. PubMed ID: 3924550
    [Abstract] [Full Text] [Related]

  • 28. Antiarrhythmic drug therapy for sustained ventricular tachycardia.
    Kienzle MG, Williams PD, Zygmont D, Doherty JU, Josephson ME.
    Heart Lung; 1984 Nov 15; 13(6):614-22. PubMed ID: 6149202
    [Abstract] [Full Text] [Related]

  • 29. New drugs for treating cardiac arrhythmias.
    Benchimol A, Desser KB.
    Postgrad Med; 1981 Jan 15; 69(1):77-84. PubMed ID: 6780988
    [Abstract] [Full Text] [Related]

  • 30. Newer antiarrhythmic drugs in children.
    Moak JP, Smith RT, Garson A.
    Am Heart J; 1987 Jan 15; 113(1):179-85. PubMed ID: 3099560
    [Abstract] [Full Text] [Related]

  • 31. Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents.
    Woosley RL, Echt DS, Roden DM.
    Am J Cardiol; 1986 Jan 31; 57(3):25B-33B. PubMed ID: 3080860
    [Abstract] [Full Text] [Related]

  • 32. Antiarrhythmic drug therapy for congestive heart failure with focus on moricizine.
    Podrid PJ, Beau SL.
    Am J Cardiol; 1990 Feb 20; 65(8):56D-64D; discussion 68D-71D. PubMed ID: 2407092
    [Abstract] [Full Text] [Related]

  • 33. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
    Bigger JT.
    Am J Cardiol; 1990 Feb 20; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
    [Abstract] [Full Text] [Related]

  • 34. Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure.
    Gottlieb SS, Kukin ML, Yushak M, Medina N, Packer M.
    Ann Intern Med; 1989 Apr 01; 110(7):505-9. PubMed ID: 2493762
    [Abstract] [Full Text] [Related]

  • 35. Hemodynamic effects of antiarrhythmic drugs.
    Block PJ, Winkle RA.
    Am J Cardiol; 1983 Sep 22; 52(6):14C-23C. PubMed ID: 6414278
    [Abstract] [Full Text] [Related]

  • 36. [Interactions of quinidine and propranolol with mexiletine, encainide, flecainide and tocainide].
    Halawa B.
    Pol Tyg Lek; 1983 Sep 22; 45(10-11):222-4. PubMed ID: 2120685
    [Abstract] [Full Text] [Related]

  • 37. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs.
    Slater W, Lampert S, Podrid PJ, Lown B.
    Am J Cardiol; 1988 Feb 01; 61(4):349-53. PubMed ID: 3124591
    [Abstract] [Full Text] [Related]

  • 38. Second generation antiarrhythmic agents: have we reached antiarrhythmic Nirvana?
    Horowitz LN, Morganroth J.
    J Am Coll Cardiol; 1987 Feb 01; 9(2):459-63. PubMed ID: 3100601
    [No Abstract] [Full Text] [Related]

  • 39. Reliability of antiarrhythmic drug plasma concentration monitoring.
    Follath F, Ganzinger U, Schuetz E.
    Clin Pharmacokinet; 1983 Feb 01; 8(1):63-82. PubMed ID: 6404580
    [Abstract] [Full Text] [Related]

  • 40. Mexiletine and tocainide: a comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing.
    Murray KT, Barbey JT, Kopelman HA, Siddoway LA, Echt DS, Woosley RL, Roden DM.
    Clin Pharmacol Ther; 1989 May 01; 45(5):553-61. PubMed ID: 2498025
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.